2Keane WF, Eknoyan G. Proteinuria, Albuminuria, Risk Assessment. Detection, Elimination (PARADE): A position paper of the National Kidney Foundation. Am J Kideny Dis, 1999,33: 1004～1010.
3Iwano M, Kubo A, Nishino T, et al. Quantification of glomerular TGF-β 1 mRNA in patients with diabetes mellitus. Kidney Int, 1996, 49: 1120.
4Kagami S, Border WA, Miller DE, et al. Angiotensin Ⅱ stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells. J Clin Invest, 1994, 93: 2431.
5Cgappel MC, Pirro MT, Sykes A. et al. Metabolism of angiotensin (1-7) by angiotensin-converting enzym. Hypertension,1998, 31: 362～367.
6Ferrario CM, Chappell MC, Tallant A, et al. Counterregulatory actions of angiotensinc (1-7). Hyperension, 1997, 30:535～541.
7Benter IF, Diz DI, Ferrario CM. Cardiovascular actions of angiotensin (1-7). Peptides, 1993, 14: 679～684.
8Oseisy, Ahima RS, Minkes RK, et al. Differential responses to angiotensin (1-7) in the felin mesenteric and hindquarters vascularbeds. EurJ Pharmacol, 1993, 235: 35～42.
9Wolf G, Ziyadeh R, Corna D, et al. The renoprotective properties of angiotensin-converting enzyme inhibitors in a chronic model of memtramous nephropathy are slely due to inhibition of angiotensin Ⅱ: evidence based on comparative studies with a receptor antagonist. Am J Kidney Dis, 1997, 29: 254～264.
10Kagami S, Kuhara T, Okada K, et al. Dual effects of angiotensin Ⅱ on the plasminogen/plasmin system in rat mesangial cells.Kidney Int, 1997, 51 (6): 664～671.
4Reidy K, Kang HM, Hostetter T, et al. Molecular mechanisms of diabetic kidney disease[J]. J Clin Invest, 2014,124(6):2333-2340.
5Wang H, Deng JL, Yue J, et al. Prostaglandin E1 for preventing the progression of diabetic kidney disease[J]. Cochrane Database Syst Rev, 2010,(5):CD006872.
6Nixon RM, Muller E, Lowy A, et al. Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach[J]. Int J Clin Pract, 2009,63(5):766-775.
7Siragy HM. Comparing angiotensin II receptor blockers on benefits beyond blood pressure[J]. Adv Ther, 2010,27(5):257-284.
8Satchell SC, Tooke JE. What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium[J]? Diabetologia, 2008,51(5):714-725.
9Christou GA,Kiortsis DN. The role of adiponectin in renal physiology and development of albuminuria[J]. J Endocrinol, 2014,221(2):R49-R61.
10Kreutz RP, Nystrom P, Kreutz Y, et al. Inhibition of platelet aggregation by prostaglandin E1(PGE1)in diabetic patients during therapy with clopidogrel and aspirin[J]. Platelets, 2013,24(2):145-150.
